001package org.hl7.fhir.r4.model.codesystems; 002 003/* 004 Copyright (c) 2011+, HL7, Inc. 005 All rights reserved. 006 007 Redistribution and use in source and binary forms, with or without modification, 008 are permitted provided that the following conditions are met: 009 010 * Redistributions of source code must retain the above copyright notice, this 011 list of conditions and the following disclaimer. 012 * Redistributions in binary form must reproduce the above copyright notice, 013 this list of conditions and the following disclaimer in the documentation 014 and/or other materials provided with the distribution. 015 * Neither the name of HL7 nor the names of its contributors may be used to 016 endorse or promote products derived from this software without specific 017 prior written permission. 018 019 THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 020 ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 021 WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 022 IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 023 INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 024 NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 025 PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 026 WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 027 ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 028 POSSIBILITY OF SUCH DAMAGE. 029 030*/ 031 032// Generated on Wed, Jan 30, 2019 16:19-0500 for FHIR v4.0.0 033 034import org.hl7.fhir.exceptions.FHIRException; 035 036public enum V3ObservationInterpretation { 037 038 /** 039 * Codes that specify interpretation of genetic analysis, such as "positive", 040 * "negative", "carrier", "responsive", etc. 041 */ 042 _GENETICOBSERVATIONINTERPRETATION, 043 /** 044 * The patient is considered as carrier based on the testing results. A carrier 045 * is an individual who carries an altered form of a gene which can lead to 046 * having a child or offspring in future generations with a genetic disorder. 047 */ 048 CAR, 049 /** 050 * The patient is considered as carrier based on the testing results. A carrier 051 * is an individual who carries an altered form of a gene which can lead to 052 * having a child or offspring in future generations with a genetic disorder. 053 * 054 * 055 * 056 * Deprecation Comment: This code is currently the same string as the print name 057 * for this concept and is inconsistent with the conventions being used for the 058 * other codes in the coding system, as it is a full word with initial 059 * capitalization, rather than an all upper case mnemonic. The recommendation 060 * from OO is to deprecate the code "Carrier" and to add "CAR" as the new active 061 * code representation for this concept. 062 */ 063 CARRIER, 064 /** 065 * Interpretations of change of quantity and/or severity. At most one of B or W 066 * and one of U or D allowed. 067 */ 068 _OBSERVATIONINTERPRETATIONCHANGE, 069 /** 070 * The current result or observation value has improved compared to the previous 071 * result or observation value (the change is significant as defined in the 072 * respective test procedure). 073 * 074 * [Note: This can be applied to quantitative or qualitative observations.] 075 */ 076 B, 077 /** 078 * The current result has decreased from the previous result for a quantitative 079 * observation (the change is significant as defined in the respective test 080 * procedure). 081 */ 082 D, 083 /** 084 * The current result has increased from the previous result for a quantitative 085 * observation (the change is significant as defined in the respective test 086 * procedure). 087 */ 088 U, 089 /** 090 * The current result or observation value has degraded compared to the previous 091 * result or observation value (the change is significant as defined in the 092 * respective test procedure). 093 * 094 * [Note: This can be applied to quantitative or qualitative observations.] 095 */ 096 W, 097 /** 098 * Technical exceptions resulting in the inability to provide an interpretation. 099 * At most one allowed. Does not imply normality or severity. 100 */ 101 _OBSERVATIONINTERPRETATIONEXCEPTIONS, 102 /** 103 * The result is below the minimum detection limit (the test procedure or 104 * equipment is the limiting factor). 105 * 106 * Synonyms: Below analytical limit, low off scale. 107 */ 108 LESS_THAN, 109 /** 110 * The result is above the maximum quantifiable limit (the test procedure or 111 * equipment is the limiting factor). 112 * 113 * Synonyms: Above analytical limit, high off scale. 114 */ 115 GREATER_THAN, 116 /** 117 * A valid result cannot be obtained for the specified component / analyte due 118 * to the presence of anti-complementary substances in the sample. 119 * 120 * 121 * 122 * Deprecation Comment: This code is being deprecated to match the status in V2 123 * Table 0078 "Interpretation Codes. 124 */ 125 AC, 126 /** 127 * There is insufficient evidence that the species in question is a good target 128 * for therapy with the drug. A categorical interpretation is not possible. 129 * 130 * [Note: A MIC with "IE" and/or a comment may be reported (without an 131 * accompanying S, I or R-categorization).] 132 */ 133 IE, 134 /** 135 * A result cannot be considered valid for the specified component / analyte or 136 * organism due to failure in the quality control testing component. 137 * 138 * 139 * 140 * Deprecation Comment: This code is being deprecated to match the status in V2 141 * Table 0078 "Interpretation Codes. 142 */ 143 QCF, 144 /** 145 * A valid result cannot be obtained for the specified organism or cell line due 146 * to the presence of cytotoxic substances in the sample or culture. 147 * 148 * 149 * 150 * Deprecation Comment: This code is being deprecated to match the status in V2 151 * Table 0078 "Interpretation Codes. 152 */ 153 TOX, 154 /** 155 * Interpretation of normality or degree of abnormality (including critical or 156 * "alert" level). Concepts in this category are mutually exclusive, i.e., at 157 * most one is allowed. 158 */ 159 _OBSERVATIONINTERPRETATIONNORMALITY, 160 /** 161 * The result or observation value is outside the reference range or expected 162 * norm (as defined for the respective test procedure). 163 * 164 * [Note: Typically applies to non-numeric results.] 165 */ 166 A, 167 /** 168 * The result or observation value is outside a reference range or expected norm 169 * at a level at which immediate action should be considered for patient safety 170 * (as defined for the respective test procedure). 171 * 172 * [Note: Typically applies to non-numeric results. Analogous to critical/panic 173 * limits for numeric results.] 174 */ 175 AA, 176 /** 177 * The result for a quantitative observation is above a reference level at which 178 * immediate action should be considered for patient safety (as defined for the 179 * respective test procedure). 180 * 181 * Synonym: Above upper panic limits. 182 */ 183 HH, 184 /** 185 * The result for a quantitative observation is below a reference level at which 186 * immediate action should be considered for patient safety (as defined for the 187 * respective test procedure). 188 * 189 * Synonym: Below lower panic limits. 190 */ 191 LL, 192 /** 193 * The result for a quantitative observation is above the upper limit of the 194 * reference range (as defined for the respective test procedure). 195 * 196 * Synonym: Above high normal 197 */ 198 H, 199 /** 200 * A test result that is significantly higher than the reference (normal) or 201 * therapeutic interval, but has not reached the critically high value and might 202 * need special attention, as defined by the laboratory or the clinician.[Note: 203 * This level is situated between 'H' and 'HH'.] 204 * 205 * 206 * Deprecation Comment: The code 'H>' is being deprecated in order to align with 207 * the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation 208 * Codes". 209 * 210 * [Note: The use of code 'H>' is non-preferred, as this code is deprecated and 211 * on track to be retired; use code 'HU' instead. 212 */ 213 H_, 214 /** 215 * A test result that is significantly higher than the reference (normal) or 216 * therapeutic interval, but has not reached the critically high value and might 217 * need special attention, as defined by the laboratory or the clinician. 218 */ 219 HU, 220 /** 221 * The result for a quantitative observation is below the lower limit of the 222 * reference range (as defined for the respective test procedure). 223 * 224 * Synonym: Below low normal 225 */ 226 L, 227 /** 228 * A test result that is significantly lower than the reference (normal) or 229 * therapeutic interval, but has not reached the critically low value and might 230 * need special attention, as defined by the laboratory or the clinician.[Note: 231 * This level is situated between 'L' and 'LL'.] 232 * 233 * 234 * Deprecation Comment: The code 'L<' is being deprecated in order to align with 235 * the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation 236 * Codes". 237 * 238 * [Note: The use of code 'L<' is non-preferred, as this code is deprecated and 239 * on track to be retired; use code 'LU' instead. 240 */ 241 L_, 242 /** 243 * A test result that is significantly lower than the reference (normal) or 244 * therapeutic interval, but has not reached the critically low value and might 245 * need special attention, as defined by the laboratory or the clinician. 246 */ 247 LU, 248 /** 249 * The result or observation value is within the reference range or expected 250 * norm (as defined for the respective test procedure). 251 * 252 * [Note: Applies to numeric or non-numeric results.] 253 */ 254 N, 255 /** 256 * Interpretations of anti-microbial susceptibility testing results 257 * (microbiology). At most one allowed. 258 */ 259 _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY, 260 /** 261 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial 262 * agent that is associated with uncertain therapeutic effect. Reference: CLSI 263 * (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 264 * Projects: ISO 20776-1, ISO 20776-2 265 * 266 * [Note 1: Bacterial strains are categorized as intermediate by applying the 267 * appropriate breakpoints in a defined phenotypic test system.] 268 * 269 * [Note 2: This class of susceptibility implies that an infection due to the 270 * isolate can be appropriately treated in body sites where the drugs are 271 * physiologically concentrated or when a high dosage of drug can be used.] 272 * 273 * [Note 3: This class also indicates a "buffer zone," to prevent small, 274 * uncontrolled, technical factors from causing major discrepancies in 275 * interpretations.] 276 * 277 * [Note 4: These breakpoints can be altered due to changes in circumstances 278 * (e.g., changes in commonly used drug dosages, emergence of new resistance 279 * mechanisms).] 280 */ 281 I, 282 /** 283 * The patient is considered as carrier based on the testing results. A carrier 284 * is an individual who carries an altered form of a gene which can lead to 285 * having a child or offspring in future generations with a genetic disorder. 286 * 287 * 288 * 289 * Deprecation Comment: This antimicrobial susceptibility test interpretation 290 * concept is recommended by OO to be deprecated as it is no longer recommended 291 * for use in susceptibility testing by CLSI (reference CLSI document M100-S22; 292 * Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility 293 * Testing; Twenty-Second Informational Supplement. Jan 2012). 294 */ 295 MS, 296 /** 297 * Use when not enough clinical trial data published by the Clinical and 298 * Laboratory Standards Institutes (CLSI) is available to establish the 299 * breakpoints for susceptible / intermediate and resistant. 300 */ 301 NCL, 302 /** 303 * A category used for isolates for which only a susceptible interpretive 304 * criterion has been designated because of the absence or rare occurrence of 305 * resistant strains. Isolates that have MICs above or zone diameters below the 306 * value indicated for the susceptible breakpoint should be reported as 307 * non-susceptible. 308 * 309 * NOTE 1: An isolate that is interpreted as non-susceptible does not 310 * necessarily mean that the isolate has a resistance mechanism. It is possible 311 * that isolates with MICs above the susceptible breakpoint that lack resistance 312 * mechanisms may be encountered within the wild-type distribution subsequent to 313 * the time the susceptible-only breakpoint is set. 314 * 315 * NOTE 2: For strains yielding results in the "nonsusceptible" category, 316 * organism identification and antimicrobial susceptibility test results should 317 * be confirmed. 318 * 319 * Synonym: decreased susceptibility. 320 */ 321 NS, 322 /** 323 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial 324 * agent that is associated with a high likelihood of therapeutic failure. 325 * Reference: CLSI 326 * (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 327 * Projects: ISO 20776-1, ISO 20776-2 328 * 329 * [Note 1: Bacterial strains are categorized as resistant by applying the 330 * appropriate breakpoints in a defined phenotypic test system.] 331 * 332 * [Note 2: This breakpoint can be altered due to changes in circumstances 333 * (e.g., changes in commonly used drug dosages, emergence of new resistance 334 * mechanisms).] 335 */ 336 R, 337 /** 338 * A category for isolates where the bacteria (e.g. enterococci) are not 339 * susceptible in vitro to a combination therapy (e.g., high-level 340 * aminoglycoside and cell wall active agent). This is predictive that this 341 * combination therapy will not be effective. 342 * 343 * 344 * Usage Note: Since the use of penicillin or ampicillin alone often results in 345 * treatment failure of serious enterococcal or other bacterial infections, 346 * combination therapy is usually indicated to enhance bactericidal activity. 347 * The synergy between a cell wall active agent (such as penicillin, ampicillin, 348 * or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or 349 * streptomycin) is best predicted by screening for high-level bacterial 350 * resistance to the aminoglycoside. 351 * 352 * 353 * Open Issue: The print name of the code is very general and the description is 354 * very specific to a pair of classes of agents, which may lead to confusion of 355 * these concepts in the future should other synergies be found. 356 */ 357 SYNR, 358 /** 359 * Bacterial strain inhibited by in vitro concentration of an antimicrobial 360 * agent that is associated with a high likelihood of therapeutic success. 361 * Reference: CLSI 362 * (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 363 * Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2 364 * 365 * [Note 1: Bacterial strains are categorized as susceptible by applying the 366 * appropriate breakpoints in a defined phenotypic system.] 367 * 368 * [Note 2: This breakpoint can be altered due to changes in circumstances 369 * (e.g., changes in commonly used drug dosages, emergence of new resistance 370 * mechanisms).] 371 */ 372 S, 373 /** 374 * A category that includes isolates with antimicrobial agent minimum inhibitory 375 * concentrations (MICs) that approach usually attainable blood and tissue 376 * levels and for which response rates may be lower than for susceptible 377 * isolates. 378 * 379 * Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion 380 * susceptibility testing of yeasts; approved guideline - second edition" - page 381 * 2. 382 */ 383 SDD, 384 /** 385 * A category for isolates where the bacteria (e.g. enterococci) are susceptible 386 * in vitro to a combination therapy (e.g., high-level aminoglycoside and cell 387 * wall active agent). This is predictive that this combination therapy will be 388 * effective. 389 * 390 * 391 * Usage Note: Since the use of penicillin or ampicillin alone often results in 392 * treatment failure of serious enterococcal or other bacterial infections, 393 * combination therapy is usually indicated to enhance bactericidal activity. 394 * The synergy between a cell wall active agent (such as penicillin, ampicillin, 395 * or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or 396 * streptomycin) is best predicted by screening for high-level bacterial 397 * resistance to the aminoglycoside. 398 * 399 * 400 * Open Issue: The print name of the code is very general and the description is 401 * very specific to a pair of classes of agents, which may lead to confusion of 402 * these concepts in the future should other synergies be found. 403 */ 404 SYNS, 405 /** 406 * The patient is considered as carrier based on the testing results. A carrier 407 * is an individual who carries an altered form of a gene which can lead to 408 * having a child or offspring in future generations with a genetic disorder. 409 * 410 * 411 * 412 * Deprecation Comment: This antimicrobial susceptibility test interpretation 413 * concept is recommended by OO to be deprecated as it is no longer recommended 414 * for use in susceptibility testing by CLSI (reference CLSI document M100-S22; 415 * Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility 416 * Testing; Twenty-Second Informational Supplement. Jan 2012). 417 */ 418 VS, 419 /** 420 * The observation/test result is interpreted as being outside the inclusion 421 * range for a particular protocol within which the result is being reported. 422 * 423 * 424 * Example: A positive result on a Hepatitis screening test. Open Issue: EX, HX, 425 * LX: These three concepts do not seem to meet a clear need in the vocabulary, 426 * and their use in observation interpretation appears likely to be covered by 427 * other existing concepts (e.g., A, H, L). The only apparent significant 428 * difference is their reference to use in protocols for exclusion of study 429 * subjects. These concepts/codes were proposed by RCRIM for use in the 430 * CTLaboratory message. They were submitted and approved in the November 2005 431 * Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs 432 * Interp_20051028154455". However, this proposal was not fully implemented in 433 * the vocabulary. The proposal recommended creation of the 434 * x_ClinicalResearchExclusion domain in ObservationInterpretation with a value 435 * set including those three concepts/codes, but there is no subdomain of that 436 * name or equivalent with a binding to either of the value sets that contain 437 * these concepts/codes. Members of the OO WG have recently attempted to contact 438 * members of RCRIM regarding these concepts, both by email and at the recent 439 * WGM in Atlanta, without response. It is felt by OO that the best course of 440 * action to take at this time is to add this comprehensive Open Issue rather 441 * than deprecate these three concepts at this time, until further discussion is 442 * held. 443 */ 444 EX, 445 /** 446 * The observation/test result is interpreted as being outside the inclusion 447 * range for a particular protocol within which the result is being reported. 448 * 449 * 450 * Example: A positive result on a Hepatitis screening test. Open Issue: EX, HX, 451 * LX: These three concepts do not seem to meet a clear need in the vocabulary, 452 * and their use in observation interpretation appears likely to be covered by 453 * other existing concepts (e.g., A, H, L). The only apparent significant 454 * difference is their reference to use in protocols for exclusion of study 455 * subjects. These concepts/codes were proposed by RCRIM for use in the 456 * CTLaboratory message. They were submitted and approved in the November 2005 457 * Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs 458 * Interp_20051028154455". However, this proposal was not fully implemented in 459 * the vocabulary. The proposal recommended creation of the 460 * x_ClinicalResearchExclusion domain in ObservationInterpretation with a value 461 * set including those three concepts/codes, but there is no subdomain of that 462 * name or equivalent with a binding to either of the value sets that contain 463 * these concepts/codes. Members of the OO WG have recently attempted to contact 464 * members of RCRIM regarding these concepts, both by email and at the recent 465 * WGM in Atlanta, without response. It is felt by OO that the best course of 466 * action to take at this time is to add this comprehensive Open Issue rather 467 * than deprecate these three concepts at this time, until further discussion is 468 * held. 469 */ 470 HX, 471 /** 472 * The numeric observation/test result is interpreted as being below the low 473 * threshold value for a particular protocol within which the result is being 474 * reported. 475 * 476 * Example: A Total White Blood Cell Count falling below a protocol-defined 477 * threshold value of 3000/mm^3 Open Issue: EX, HX, LX: These three concepts do 478 * not seem to meet a clear need in the vocabulary, and their use in observation 479 * interpretation appears likely to be covered by other existing concepts (e.g., 480 * A, H, L). The only apparent significant difference is their reference to use 481 * in protocols for exclusion of study subjects. These concepts/codes were 482 * proposed by RCRIM for use in the CTLaboratory message. They were submitted 483 * and approved in the November 2005 Harmonization cycle in proposal 484 * "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this 485 * proposal was not fully implemented in the vocabulary. The proposal 486 * recommended creation of the x_ClinicalResearchExclusion domain in 487 * ObservationInterpretation with a value set including those three 488 * concepts/codes, but there is no subdomain of that name or equivalent with a 489 * binding to either of the value sets that contain these concepts/codes. 490 * Members of the OO WG have recently attempted to contact members of RCRIM 491 * regarding these concepts, both by email and at the recent WGM in Atlanta, 492 * without response. It is felt by OO that the best course of action to take at 493 * this time is to add this comprehensive Open Issue rather than deprecate these 494 * three concepts at this time, until further discussion is held. 495 */ 496 LX, 497 /** 498 * Hold for Medical Review 499 * 500 * 501 * Usage Note: This code is not intended for use in V3 artifacts. It is included 502 * in the code system to maintain alignment with the V2 Table 0078 503 * "Interpretation Codes." 504 */ 505 HM, 506 /** 507 * Interpretations of the presence or absence of a component / analyte or 508 * organism in a test or of a sign in a clinical observation. In keeping with 509 * laboratory data processing practice, these concepts provide a categorical 510 * interpretation of the "meaning" of the quantitative value for the same 511 * observation. 512 */ 513 OBSERVATIONINTERPRETATIONDETECTION, 514 /** 515 * The specified component / analyte, organism or clinical sign could neither be 516 * declared positive / negative nor detected / not detected by the performed 517 * test or procedure. 518 * 519 * 520 * Usage Note: For example, if the specimen was degraded, poorly processed, or 521 * was missing the required anatomic structures, then "indeterminate" (i.e. 522 * "cannot be determined") is the appropriate response, not "equivocal". 523 */ 524 IND, 525 /** 526 * The test or procedure was successfully performed, but the results are 527 * borderline and can neither be declared positive / negative nor detected / not 528 * detected according to the current established criteria. 529 */ 530 E, 531 /** 532 * An absence finding of the specified component / analyte, organism or clinical 533 * sign based on the established threshold of the performed test or procedure. 534 * 535 * [Note: Negative does not necessarily imply the complete absence of the 536 * specified item.] 537 */ 538 NEG, 539 /** 540 * The presence of the specified component / analyte, organism or clinical sign 541 * could not be determined within the limit of detection of the performed test 542 * or procedure. 543 */ 544 ND, 545 /** 546 * A presence finding of the specified component / analyte, organism or clinical 547 * sign based on the established threshold of the performed test or procedure. 548 */ 549 POS, 550 /** 551 * The measurement of the specified component / analyte, organism or clinical 552 * sign above the limit of detection of the performed test or procedure. 553 */ 554 DET, 555 /** 556 * Interpretation of the observed result taking into account additional 557 * information (contraindicators) about the patient's situation. Concepts in 558 * this category are mutually exclusive, i.e., at most one is allowed. 559 */ 560 OBSERVATIONINTERPRETATIONEXPECTATION, 561 /** 562 * This result has been evaluated in light of known contraindicators. Once those 563 * contraindicators have been taken into account the result is determined to be 564 * "Expected" (e.g., presence of drugs in a patient that is taking prescription 565 * medication for pain management). 566 */ 567 EXP, 568 /** 569 * This result has been evaluated in light of known contraindicators. Once those 570 * contraindicators have been taken into account the result is determined to be 571 * "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is 572 * taking prescription medication for pain management). 573 */ 574 UNE, 575 /** 576 * Interpretation qualifiers in separate OBX segments 577 * 578 * 579 * Usage Note: This code is not intended for use in V3 artifacts. It is included 580 * in the code system to maintain alignment with the V2 Table 0078 581 * "Interpretation Codes." 582 */ 583 OBX, 584 /** 585 * Interpretations of the presence and level of reactivity of the specified 586 * component / analyte with the reagent in the performed laboratory test. 587 */ 588 REACTIVITYOBSERVATIONINTERPRETATION, 589 /** 590 * An absence finding used to indicate that the specified component / analyte 591 * did not react measurably with the reagent. 592 */ 593 NR, 594 /** 595 * A presence finding used to indicate that the specified component / analyte 596 * reacted with the reagent above the reliably measurable limit of the performed 597 * test. 598 */ 599 RR, 600 /** 601 * A weighted presence finding used to indicate that the specified component / 602 * analyte reacted with the reagent, but below the reliably measurable limit of 603 * the performed test. 604 */ 605 WR, 606 /** 607 * added to help the parsers 608 */ 609 NULL; 610 611 public static V3ObservationInterpretation fromCode(String codeString) throws FHIRException { 612 if (codeString == null || "".equals(codeString)) 613 return null; 614 if ("_GeneticObservationInterpretation".equals(codeString)) 615 return _GENETICOBSERVATIONINTERPRETATION; 616 if ("CAR".equals(codeString)) 617 return CAR; 618 if ("Carrier".equals(codeString)) 619 return CARRIER; 620 if ("_ObservationInterpretationChange".equals(codeString)) 621 return _OBSERVATIONINTERPRETATIONCHANGE; 622 if ("B".equals(codeString)) 623 return B; 624 if ("D".equals(codeString)) 625 return D; 626 if ("U".equals(codeString)) 627 return U; 628 if ("W".equals(codeString)) 629 return W; 630 if ("_ObservationInterpretationExceptions".equals(codeString)) 631 return _OBSERVATIONINTERPRETATIONEXCEPTIONS; 632 if ("<".equals(codeString)) 633 return LESS_THAN; 634 if (">".equals(codeString)) 635 return GREATER_THAN; 636 if ("AC".equals(codeString)) 637 return AC; 638 if ("IE".equals(codeString)) 639 return IE; 640 if ("QCF".equals(codeString)) 641 return QCF; 642 if ("TOX".equals(codeString)) 643 return TOX; 644 if ("_ObservationInterpretationNormality".equals(codeString)) 645 return _OBSERVATIONINTERPRETATIONNORMALITY; 646 if ("A".equals(codeString)) 647 return A; 648 if ("AA".equals(codeString)) 649 return AA; 650 if ("HH".equals(codeString)) 651 return HH; 652 if ("LL".equals(codeString)) 653 return LL; 654 if ("H".equals(codeString)) 655 return H; 656 if ("H>".equals(codeString)) 657 return H_; 658 if ("HU".equals(codeString)) 659 return HU; 660 if ("L".equals(codeString)) 661 return L; 662 if ("L<".equals(codeString)) 663 return L_; 664 if ("LU".equals(codeString)) 665 return LU; 666 if ("N".equals(codeString)) 667 return N; 668 if ("_ObservationInterpretationSusceptibility".equals(codeString)) 669 return _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY; 670 if ("I".equals(codeString)) 671 return I; 672 if ("MS".equals(codeString)) 673 return MS; 674 if ("NCL".equals(codeString)) 675 return NCL; 676 if ("NS".equals(codeString)) 677 return NS; 678 if ("R".equals(codeString)) 679 return R; 680 if ("SYN-R".equals(codeString)) 681 return SYNR; 682 if ("S".equals(codeString)) 683 return S; 684 if ("SDD".equals(codeString)) 685 return SDD; 686 if ("SYN-S".equals(codeString)) 687 return SYNS; 688 if ("VS".equals(codeString)) 689 return VS; 690 if ("EX".equals(codeString)) 691 return EX; 692 if ("HX".equals(codeString)) 693 return HX; 694 if ("LX".equals(codeString)) 695 return LX; 696 if ("HM".equals(codeString)) 697 return HM; 698 if ("ObservationInterpretationDetection".equals(codeString)) 699 return OBSERVATIONINTERPRETATIONDETECTION; 700 if ("IND".equals(codeString)) 701 return IND; 702 if ("E".equals(codeString)) 703 return E; 704 if ("NEG".equals(codeString)) 705 return NEG; 706 if ("ND".equals(codeString)) 707 return ND; 708 if ("POS".equals(codeString)) 709 return POS; 710 if ("DET".equals(codeString)) 711 return DET; 712 if ("ObservationInterpretationExpectation".equals(codeString)) 713 return OBSERVATIONINTERPRETATIONEXPECTATION; 714 if ("EXP".equals(codeString)) 715 return EXP; 716 if ("UNE".equals(codeString)) 717 return UNE; 718 if ("OBX".equals(codeString)) 719 return OBX; 720 if ("ReactivityObservationInterpretation".equals(codeString)) 721 return REACTIVITYOBSERVATIONINTERPRETATION; 722 if ("NR".equals(codeString)) 723 return NR; 724 if ("RR".equals(codeString)) 725 return RR; 726 if ("WR".equals(codeString)) 727 return WR; 728 throw new FHIRException("Unknown V3ObservationInterpretation code '" + codeString + "'"); 729 } 730 731 public String toCode() { 732 switch (this) { 733 case _GENETICOBSERVATIONINTERPRETATION: 734 return "_GeneticObservationInterpretation"; 735 case CAR: 736 return "CAR"; 737 case CARRIER: 738 return "Carrier"; 739 case _OBSERVATIONINTERPRETATIONCHANGE: 740 return "_ObservationInterpretationChange"; 741 case B: 742 return "B"; 743 case D: 744 return "D"; 745 case U: 746 return "U"; 747 case W: 748 return "W"; 749 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: 750 return "_ObservationInterpretationExceptions"; 751 case LESS_THAN: 752 return "<"; 753 case GREATER_THAN: 754 return ">"; 755 case AC: 756 return "AC"; 757 case IE: 758 return "IE"; 759 case QCF: 760 return "QCF"; 761 case TOX: 762 return "TOX"; 763 case _OBSERVATIONINTERPRETATIONNORMALITY: 764 return "_ObservationInterpretationNormality"; 765 case A: 766 return "A"; 767 case AA: 768 return "AA"; 769 case HH: 770 return "HH"; 771 case LL: 772 return "LL"; 773 case H: 774 return "H"; 775 case H_: 776 return "H>"; 777 case HU: 778 return "HU"; 779 case L: 780 return "L"; 781 case L_: 782 return "L<"; 783 case LU: 784 return "LU"; 785 case N: 786 return "N"; 787 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: 788 return "_ObservationInterpretationSusceptibility"; 789 case I: 790 return "I"; 791 case MS: 792 return "MS"; 793 case NCL: 794 return "NCL"; 795 case NS: 796 return "NS"; 797 case R: 798 return "R"; 799 case SYNR: 800 return "SYN-R"; 801 case S: 802 return "S"; 803 case SDD: 804 return "SDD"; 805 case SYNS: 806 return "SYN-S"; 807 case VS: 808 return "VS"; 809 case EX: 810 return "EX"; 811 case HX: 812 return "HX"; 813 case LX: 814 return "LX"; 815 case HM: 816 return "HM"; 817 case OBSERVATIONINTERPRETATIONDETECTION: 818 return "ObservationInterpretationDetection"; 819 case IND: 820 return "IND"; 821 case E: 822 return "E"; 823 case NEG: 824 return "NEG"; 825 case ND: 826 return "ND"; 827 case POS: 828 return "POS"; 829 case DET: 830 return "DET"; 831 case OBSERVATIONINTERPRETATIONEXPECTATION: 832 return "ObservationInterpretationExpectation"; 833 case EXP: 834 return "EXP"; 835 case UNE: 836 return "UNE"; 837 case OBX: 838 return "OBX"; 839 case REACTIVITYOBSERVATIONINTERPRETATION: 840 return "ReactivityObservationInterpretation"; 841 case NR: 842 return "NR"; 843 case RR: 844 return "RR"; 845 case WR: 846 return "WR"; 847 case NULL: 848 return null; 849 default: 850 return "?"; 851 } 852 } 853 854 public String getSystem() { 855 return "http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretation"; 856 } 857 858 public String getDefinition() { 859 switch (this) { 860 case _GENETICOBSERVATIONINTERPRETATION: 861 return "Codes that specify interpretation of genetic analysis, such as \"positive\", \"negative\", \"carrier\", \"responsive\", etc."; 862 case CAR: 863 return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder."; 864 case CARRIER: 865 return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code \"Carrier\" and to add \"CAR\" as the new active code representation for this concept."; 866 case _OBSERVATIONINTERPRETATIONCHANGE: 867 return "Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed."; 868 case B: 869 return "The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 870 case D: 871 return "The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 872 case U: 873 return "The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 874 case W: 875 return "The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 876 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: 877 return "Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity."; 878 case LESS_THAN: 879 return "The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Below analytical limit, low off scale."; 880 case GREATER_THAN: 881 return "The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Above analytical limit, high off scale."; 882 case AC: 883 return "A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 884 case IE: 885 return "There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.\r\n\n [Note: A MIC with \"IE\" and/or a comment may be reported (without an accompanying S, I or R-categorization).]"; 886 case QCF: 887 return "A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 888 case TOX: 889 return "A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture.\r\n\n \n \n Deprecation Comment: \n This code is being deprecated to match the status in V2 Table 0078 \"Interpretation Codes."; 890 case _OBSERVATIONINTERPRETATIONNORMALITY: 891 return "Interpretation of normality or degree of abnormality (including critical or \"alert\" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 892 case A: 893 return "The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results.]"; 894 case AA: 895 return "The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.]"; 896 case HH: 897 return "The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Above upper panic limits."; 898 case LL: 899 return "The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Below lower panic limits."; 900 case H: 901 return "The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Above high normal"; 902 case H_: 903 return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.]\r\n\n \n Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for \"Very high\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead."; 904 case HU: 905 return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician."; 906 case L: 907 return "The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Below low normal"; 908 case L_: 909 return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.]\r\n\n \n Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for \"Very low\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead."; 910 case LU: 911 return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician."; 912 case N: 913 return "The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Applies to numeric or non-numeric results.]"; 914 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: 915 return "Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed."; 916 case I: 917 return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]\r\n\n [Note 3: This class also indicates a \"buffer zone,\" to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]\r\n\n [Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 918 case MS: 919 return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 920 case NCL: 921 return "Use when not enough clinical trial data published by the Clinical and Laboratory Standards Institutes (CLSI) is available to establish the breakpoints for susceptible / intermediate and resistant."; 922 case NS: 923 return "A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.\r\n\n NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. \r\n\n NOTE 2: For strains yielding results in the \"nonsusceptible\" category, organism identification and antimicrobial susceptibility test results should be confirmed.\r\n\n Synonym: decreased susceptibility."; 924 case R: 925 return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) \nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 926 case SYNR: 927 return "A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 928 case S: 929 return "Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nSynonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 930 case SDD: 931 return "A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.\r\n\n Reference: CLSI document M44-A2 2009 \"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition\" - page 2."; 932 case SYNS: 933 return "A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 934 case VS: 935 return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 936 case EX: 937 return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.\nThese concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.\nMembers of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 938 case HX: 939 return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 940 case LX: 941 return "The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.\r\n\n Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 942 case HM: 943 return "Hold for Medical Review\r\n\n \n Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\""; 944 case OBSERVATIONINTERPRETATIONDETECTION: 945 return "Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the \"meaning\" of the quantitative value for the same observation."; 946 case IND: 947 return "The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.\r\n\n \n Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then \"indeterminate\" (i.e. \"cannot be determined\") is the appropriate response, not \"equivocal\"."; 948 case E: 949 return "The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria."; 950 case NEG: 951 return "An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.\r\n\n [Note: Negative does not necessarily imply the complete absence of the specified item.]"; 952 case ND: 953 return "The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure."; 954 case POS: 955 return "A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure."; 956 case DET: 957 return "The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure."; 958 case OBSERVATIONINTERPRETATIONEXPECTATION: 959 return "Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 960 case EXP: 961 return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Expected\" (e.g., presence of drugs in a patient that is taking prescription medication for pain management)."; 962 case UNE: 963 return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Unexpected\" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management)."; 964 case OBX: 965 return "Interpretation qualifiers in separate OBX segments\r\n\n \n Usage Note: This code is not intended for use in V3 artifacts. It is included in the code system to maintain alignment with the V2 Table 0078 \"Interpretation Codes.\""; 966 case REACTIVITYOBSERVATIONINTERPRETATION: 967 return "Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test."; 968 case NR: 969 return "An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent."; 970 case RR: 971 return "A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test."; 972 case WR: 973 return "A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test."; 974 case NULL: 975 return null; 976 default: 977 return "?"; 978 } 979 } 980 981 public String getDisplay() { 982 switch (this) { 983 case _GENETICOBSERVATIONINTERPRETATION: 984 return "GeneticObservationInterpretation"; 985 case CAR: 986 return "Carrier"; 987 case CARRIER: 988 return "Carrier"; 989 case _OBSERVATIONINTERPRETATIONCHANGE: 990 return "ObservationInterpretationChange"; 991 case B: 992 return "Better"; 993 case D: 994 return "Significant change down"; 995 case U: 996 return "Significant change up"; 997 case W: 998 return "Worse"; 999 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: 1000 return "ObservationInterpretationExceptions"; 1001 case LESS_THAN: 1002 return "Off scale low"; 1003 case GREATER_THAN: 1004 return "Off scale high"; 1005 case AC: 1006 return "Anti-complementary substances present"; 1007 case IE: 1008 return "Insufficient evidence"; 1009 case QCF: 1010 return "Quality control failure"; 1011 case TOX: 1012 return "Cytotoxic substance present"; 1013 case _OBSERVATIONINTERPRETATIONNORMALITY: 1014 return "ObservationInterpretationNormality"; 1015 case A: 1016 return "Abnormal"; 1017 case AA: 1018 return "Critical abnormal"; 1019 case HH: 1020 return "Critical high"; 1021 case LL: 1022 return "Critical low"; 1023 case H: 1024 return "High"; 1025 case H_: 1026 return "Significantly high"; 1027 case HU: 1028 return "Significantly high"; 1029 case L: 1030 return "Low"; 1031 case L_: 1032 return "Significantly low"; 1033 case LU: 1034 return "Significantly low"; 1035 case N: 1036 return "Normal"; 1037 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: 1038 return "ObservationInterpretationSusceptibility"; 1039 case I: 1040 return "Intermediate"; 1041 case MS: 1042 return "moderately susceptible"; 1043 case NCL: 1044 return "No CLSI defined breakpoint"; 1045 case NS: 1046 return "Non-susceptible"; 1047 case R: 1048 return "Resistant"; 1049 case SYNR: 1050 return "Synergy - resistant"; 1051 case S: 1052 return "Susceptible"; 1053 case SDD: 1054 return "Susceptible-dose dependent"; 1055 case SYNS: 1056 return "Synergy - susceptible"; 1057 case VS: 1058 return "very susceptible"; 1059 case EX: 1060 return "outside threshold"; 1061 case HX: 1062 return "above high threshold"; 1063 case LX: 1064 return "below low threshold"; 1065 case HM: 1066 return "Hold for Medical Review"; 1067 case OBSERVATIONINTERPRETATIONDETECTION: 1068 return "ObservationInterpretationDetection"; 1069 case IND: 1070 return "Indeterminate"; 1071 case E: 1072 return "Equivocal"; 1073 case NEG: 1074 return "Negative"; 1075 case ND: 1076 return "Not detected"; 1077 case POS: 1078 return "Positive"; 1079 case DET: 1080 return "Detected"; 1081 case OBSERVATIONINTERPRETATIONEXPECTATION: 1082 return "ObservationInterpretationExpectation"; 1083 case EXP: 1084 return "Expected"; 1085 case UNE: 1086 return "Unexpected"; 1087 case OBX: 1088 return "Interpretation qualifiers in separate OBX segments"; 1089 case REACTIVITYOBSERVATIONINTERPRETATION: 1090 return "ReactivityObservationInterpretation"; 1091 case NR: 1092 return "Non-reactive"; 1093 case RR: 1094 return "Reactive"; 1095 case WR: 1096 return "Weakly reactive"; 1097 case NULL: 1098 return null; 1099 default: 1100 return "?"; 1101 } 1102 } 1103 1104}